drug · oligonucleotide
LEQVIO
updated 6mo agoby $NVS NOVARTIS AG🔗 ChEMBL
community read0 votes
🐶 often sniffed alongside
top 2Oligonucleotide drug with a maximum clinical stage of Approval (across all indications), with an approval for 3 indications.
targets
PCSK9 mRNA
all catalysts(0)
nothing on the calendar yet
Trials studying LEQVIO
- phase4LDL-C Optimization Using Inclisiran in Patients in Which Drug-Drug Interactions Limit LDL Lowering
- phase3Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events
- phase4Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention
- phase2Phase 2 Clinical Study of MWX203 Injection Alone or in Combination With Inclisiran Sodium Injection in Patients With Mixed Dyslipidemia
- phase3A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
- phase3Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease
- phase4Study of Efficacy, Safety, Tolerability and Quality of Life of Inclisiran (KJX839) vs Placebo, on Top of Ongoing Individually Optimized Lipid-lowering Therapy, in Participants With Hypercholesterolemia
- phase2A Study to Evaluate the Safety, Efficacy of SYH2053 in Chinese Participants With Non-familial Hypercholesterolemia and Mixed Hyperlipidemia
News(10)
- Novartis projects slowed growth, pins hopes on billions in pipeline potentialWith Kisqali going off patent and decreasing prices impacting sales, Novartis has narrowed sales guidance to 5% growth. But management remains steadfast that they have a plan to get back on track.biospace · 4h ago
- Novartis CEO argues shareholders ‘happy overall’ with strategy, calls for COINS Act adjustmentDespite a bumpy few months for Novartis that saw a couple of high-profile clinical setbacks, CEO Vas Narasimhan has told Fierce he believes most shareholders remain onside with the company’s strategy.fiercebiotech · 16h ago
- Novartis faces $1.9B hit from Avidity fail but maintains confidence in $12B buyNovartis remains "very happy" with its $12 billion acquisition of Avidity Biosciences, despite a Phase 3 disappointment for the antibody-oligonucleotide conjugate del-desiran.biospace · 23d ago
- Novartis shareholder calls for board overhaul following costly deal setbacks: ReutersNovartis’ recent dual clinical setbacks have prompted questions from a major shareholder about the board’s oversight of dealmaking.fiercebiotech · 2mo ago
- Scribe’s early-stage IPO standout defies biotech’s derisking trendScribe Therapeutics’ one-time epigenetic treatment is designed to slash the adherence burden of chronic cholesterol-lowering therapies while sidestepping the irreversibility of gene editing.biospace · 3mo ago
- Scribe’s Benjamin Oakes on a rare IPO and bringing CRISPR to the massesThe CEO spoke with BioPharma Dive about convincing investors to buy into the first gene editing IPO in more than two years.biopharma_dive · 3mo ago
- Scribe records upsized $129M IPO to bankroll lipid-lowering genetic medsIn vivo gene editing outfit Scribe Therapeutics has priced its IPO at $128.7 million, surpassing the $96 million goal set out earlier this week.fiercebiotech · 3mo ago
- Novartis climbs on upbeat drug sales as key readouts loomA return to quarterly sales growth boosted shares higher on Tuesday, though a handful of coming study results will have a bigger impact on the company’s long-term outlook.biopharma_dive · 4mo ago
- Scribe aims for $96M IPO to fund clinical push for lipid-lowering genetic medsScribe Therapeutics has put its IPO plans down on paper, showing the genetic medicine company hopes to raise $96 million through its public listing.fiercebiotech · 4mo ago
- Merck dives into cholesterol with first FDA approval for oral PCSK9 inhibitorMerck’s once-daily pill is the first oral PCSK9 inhibitor to hit the market for high cholesterol, beating AstraZeneca in the race to develop more accessible treatment options.biospace · 4mo ago
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that